for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cardlytics Inc

CDLX.OQ

Latest Trade

38.13USD

Change

0.01(+0.03%)

Volume

20,368

Today's Range

37.70

 - 

38.33

52 Week Range

9.93

 - 

39.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Cardlytics Inc - Announced Pricing Of An Underwritten Public Offering Of 2.69 Million Shares Priced At $34 Per Share

Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CARDLYTICS INC - ANNOUNCED PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 2.69 MILLION SHARES PRICED AT $34 PER SHARE.

Cardlytics Announces Proposed Public Offering Of Common Stock

Sept 9 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 2.69 MILLION COMMON SHARES.OF 2.69 MILLION SHARES, 1.5 MILLION ARE BEING OFFERED BY CO & 1.19 MILLION SHARES BY EXISTING STOCKHOLDERS.

Cardlytics Reports Q2 Loss Per Share Of $0.29

Aug 8 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 REVENUE $48.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $43.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.Q2 NON-GAAP LOSS PER SHARE $0.12.QTRLY BILLINGS $73.8 MILLION, UP 43%.SEES FY 2019 REVENUE $180.0 MILLION - $190.0 MILLION.SEES Q3 BILLINGS $70.0 MILLION - $76.0 MILLION.SEES FY 2019 BILLINGS $275.0 MILLION - $290.0 MILLION.SEES Q3 REVENUE $46.0 MILLION - $50.0 MILLION.

Cardlytics Q2 Non-Gaap Loss Per Share $0.12

Aug 8 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 REVENUE $48.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $43.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.Q2 NON-GAAP LOSS PER SHARE $0.12.QTRLY BILLINGS $73.8 MILLION, UP 43%.SEES FY 2019 BILLINGS $275.0 - $290.0.SEES FY 2019 REVENUE $180.0 - $190.0.SEES Q3 $46.0 MILLION - $50.0 MILLION.SEES Q3 BILLINGS $70.0 MILLION - $76.0 MILLION.

Cardlytics Inc Files For Mixed Shelf Of Upto $100 Mln

July 27 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.CARDLYTICS INC IN ADDITION, SECONDARY OFFERING OF UP TO 4.0 MILLION SHARES OF COMMON STOCK.

Cardlytics Says Co And Pacific Western Bank Entered Second Amendment Dated May 21, 2018 - SEC Filing

May 14 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS SAYS CO AND PACIFIC WESTERN BANK ENTERED INTO A SECOND AMENDMENT DATED MAY 21, 2018 - SEC FILING.CARDLYTICS INC - PURSUANT TO AMENDMENT, CO & LENDER AGREED TO INCREASE ASSET-BASED REVOLVING LINE OF CREDIT UNDER LSA FROM $30.0 MILLION TO $40.0 MILLION.CARDLYTICS INC - COMPANY AGREED TO REPAY $10.0 MILLION OF PRINCIPAL BALANCE OF TERM LOAN OUTSTANDING UNDER LSA ON MAY 14, 2019.CARDLYTICS INC - AMENDMENT ALSO EXTENDED MATURITY DATE FOR BORROWINGS UNDER LSA TO MAY 14, 2021.

Cardlytics Reports Q4 GAAP Loss Per Share Of $0.53

March 5 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS.Q4 GAAP LOSS PER SHARE $0.53.Q4 REVENUE $47.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $45.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.17 -- REFINITIV IBES DATA.Q4 NON-GAAP LOSS PER SHARE $0.06.SEES Q1 2019 REVENUE IN THE RANGE OF $34.5 MILLION TO $36.5 MILLION.SEES Q1 2019 NON-GAAP ADJUSTED CONTRIBUTION IN THE RANGE OF $15.5 MILLION TO $16.5 MILLION.Q4 REVENUE VIEW $45.8 MILLION -- REFINITIV IBES DATA.

Cardlytics Sees Q4 2018 Revenue $47 Mln To $48 Mln

Jan 14 (Reuters) - Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES PRELIMINARY FOURTH QUARTER 2018 FINANCIAL RESULTS.SEES Q4 2018 REVENUE $47 MILLION TO $48 MILLION.FI MAUS FOR THE FOURTH QUARTER ARE EXPECTED TO EXCEED 80.0 MILLION.FI MAUS FOR Q4 ARE EXPECTED TO EXCEED 80.0 MILLION..Q4 REVENUE VIEW $44.1 MILLION -- REFINITIV IBES DATA.

Cardlytics Q3 Non-GAAP Loss Per Share $0.15

Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 GAAP LOSS PER SHARE $0.40.Q3 REVENUE $34.6 MILLION VERSUS I/B/E/S VIEW $37.6 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S.Q3 NON-GAAP LOSS PER SHARE $0.15.QTRLY CARDLYTICS DIRECT REVENUE WAS $34.4 MILLION, AN INCREASE OF 14%, COMPARED TO $30.2 MILLION IN Q3 OF 2017.SEES FY 2018 REVENUE IN THE RANGE OF $146.0 MILLION - $148.0 MILLION.SEES Q4 2018 REVENUE $43.0 MILLION - $45.0 MILLION.SEES Q4 2018 REVENUE IN THE RANGE OF $43.0 MILLION - $45.0 MILLION.SEES 2018 REVENUE $146.0 MILLION - $148.0 MILLION.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $20.1.SEES Q4 2018 NON-GAAP EARNINGS PER SHARE $21.4.

Cardlytics Q2 GAAP Loss Per Share $0.64

Cardlytics Inc <CDLX.O>::CARDLYTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 GAAP LOSS PER SHARE $0.64.Q2 REVENUE $35.6 MILLION VERSUS I/B/E/S VIEW $34.8 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.53 -- THOMSON REUTERS I/B/E/S.Q2 NON-GAAP LOSS PER SHARE $0.21.SEES Q3 2018 REVENUE $36.0 MILLION - $38.0 MILLION.SEES FULL YEAR 2018 REVENUE $153.0 MILLION - $156.0 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up